Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plexxikon's PLX3397 selected for I-SPY 2 breast cancer trial

This article was originally published in Scrip

Executive Summary

Daiichi Sankyo subsidiary Plexxikon's oral small molecule PLX3397 joined the ranks of Amgen's trebananib and ganitumab as well as ganetespib from Synta Pharmaceuticals in the large, multi-arm, investigator-sponsored breast cancer clinical trial known as I-SPY 2.

You may also be interested in...



I-SPY 2 Helping To Normalize Adaptive Trial Designs

Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.

Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023

Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.

Focus On Execution Pays Off, Sets BMS Up For Growth In 2023

Revenue declined in 2022 but the company expects it to increase 2% this year, offsetting an anticipated $3.5bn drop in Revlimid sales as new launches generate $4bn in 2023.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC027214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel